AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02112565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04530227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Camrelizumab
Description: PD-1
Study NCT04451720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study NCT04530227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy
Study NCT04530227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: chemotherapy
Study NCT03762187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Individuals select important values and then write about why that value is important to them.
Study NCT03762187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive living counseling
Description: Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
Study NCT03762187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive living counseling
Description: Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
Study NCT02574273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Group / Treatment As Usual
Description: The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
Study NCT03633110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-009 Adjuvanted Vaccine
Description: GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
Study NCT03633110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
Study NCT03633110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
Study NCT02673463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg once daily
Study NCT02673463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical to spironolactone, once daily
Study NCT01151371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon B contact lens
Description: Silicone Hydrogel Daily Disposable Contact Lenses
Study NCT01151371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A contact lens
Description: Conventional Hydrogel Daily Disposable Contact Lenses
Study NCT01151371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B contact lens
Description: Silicone Hydrogel Monthly Replacement Contact Lenses
Study NCT04329910 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only
Study NCT00747084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
Study NCT02555176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Follow a low-carbohydrate diet
Study NCT04344275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -Scapular endurance test
Description: The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
Study NCT04344275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: -Scapular endurance test
Description: The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
Study NCT04344275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -Muscle strength test
Description: Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
Study NCT04344275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: -Muscle strength test
Description: Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
Study NCT03229109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrophon dehydration body monitor
Description: Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
Study NCT03719742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sponsor Test Products
Description: Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
Study NCT00725049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant (Nanotite)
Description: Root form titanium dental implant
Study NCT02551263 — intervention group
Intervention type: DRUG
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
Study NCT02038335 — intervention group
Intervention type: DRUG
Intervention: DMPA
Description: Depot medroxyprogesterone acetate
Study NCT02038335 — intervention group
Intervention type: DRUG
Intervention: NET-EN
Description: Norethisterone enantate
Study NCT02038335 — intervention group
Intervention type: DRUG
Intervention: MPA/E2
Description: Medroxyprogesterone acetate and estradiol cypionate
Study NCT02038335 — intervention group
Intervention type: DEVICE
Intervention: LNG-I
Description: Levonorgestrel subdermal implant
Study NCT02038335 — intervention group
Intervention type: DEVICE
Intervention: ENG-I
Description: Etonogestrel subdermal implant
Study NCT02038335 — intervention group
Intervention type: DEVICE
Intervention: Cu-IUD
Description: Copper IUD
Study NCT00448344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-supported
Description: Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
Study NCT00448344 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Telephone counseling
Description: Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
Study NCT01335620 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: 400 mg twice daily
Study NCT01335620 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir
Description: 245 mg once daily
Study NCT00410150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helium-oxygen-driven albuterol nebulizer
Description: Subjects will be treated with continuous albuterol nebs with Heliox
Study NCT01335620 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine
Description: 200mg once daily
Study NCT02467543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20% Ethanol
Description: Unmedicated 20% Ethanol
Study NCT02510001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
Study NCT02510001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
Study NCT00410150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Subjects will be treated with continuous albuterol nebs in oxygen
Study NCT02510001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
Study NCT02511886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen Placarbil
Description: Arbaclofen Placarbil
Study NCT02511886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched tablets
Study NCT01301313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
Study NCT01301313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intensified inotropic treatment
Description: Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
Study NCT00730808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PreOP Booster (food for special medical purposes)
Description: 3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
Study NCT00730808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP Booster (food for special medical purposes)
Description: 3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
Study NCT03307356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Transplant of a uterus from a donor, deceased or living
Study NCT01615614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
Study NCT01615614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
Study NCT02467543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viburnum opulus 3X
Description: Viburnum opulus 3X in a vehicle of 20% ethanol.
Study NCT04099589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Gemcitabine/Cisplatin plus Toripalimab
Study NCT00981695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
Study NCT02696980 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Positive Expiratory Pressure
Description: Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
Study NCT02696980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure
Description: Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
Study NCT01362894 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A contact lens
Description: Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
Study NCT01362894 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A contact lens
Description: Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
Study NCT02780284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: 150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
Study NCT03529968 — intervention group
Intervention type: PROCEDURE
Intervention: esophagectomy
Description: Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
Study NCT03982680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/kg on d1 and d15 q4W\*4cycles，then 3mg/kg q3w for 1 year in total
Study NCT03982680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2 on d1 and d15 q4W\*4cycles
Study NCT03982680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5- fluorine pyrimidine
Description: 400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W\*4cycles
Study NCT05314335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology socks+walking
Description: Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
Study NCT05314335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Just walking
Description: Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
Study NCT00031759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Study NCT00031759 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablative or excisional therapy
Study NCT00031759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative or excisional therapy
Study NCT04190901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Black Male Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
Study NCT04190901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Black Female Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
Study NCT04190901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated White Male Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
Study NCT04190901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated White Female Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
Study NCT00961727 — intervention group
Intervention type: OTHER
Intervention: Bedside Paediatric Early Warning System (Bedside PEWS)
Description: The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
Study NCT04167449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HRG80 Hydroponic Red Ginseng
Description: Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
Study NCT04167449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional White Ginseng
Description: Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
Study NCT04167449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical placebo capsule containing rice flour
Study NCT04366011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
Study NCT04366011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capnometry Assisted Respiratory Training (CART)
Description: CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
Study NCT01048710 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03301207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
Study NCT03301207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg
Description: Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
Study NCT03301207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
Study NCT04522167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYB203 (Proposed aflibercept biosimilar)
Description: Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Study NCT04522167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea® (Aflibercept)
Description: Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Study NCT01107314 — intervention group
Intervention type: OTHER
Intervention: Phlebotomy
Description: Blood draws (total 48 cc blood)
Study NCT01409876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: interstitial image- guided PDR/HDR brachytherapy
Study NCT01641601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient transcervical Foley balloon
Description: A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
Study NCT00863499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short Acting Methylphenidate
Description: Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
Study NCT00863499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long Acting Methylphenidate
Description: Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
Study NCT03629522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8Mg/4mL Injection
Description: investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
Study NCT03629522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8Mg/4mL Injection
Description: investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
Study NCT03053570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Description: use Cryoballoon to isolation the Pulmonary Vein
Study NCT03053570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy(Contact Force)
Description: use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein